Episode Details

Alcon Inc. (ALC) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): core diluted EPS $0.84 against a $0.77 bar, a 9.1% beat, on net sales of $2,782M, up 8% reported and 7% constant currency. IFRS diluted EPS was $0.00 after a $402M PowerVision write-off. Full-year core EPS growth guidance was RAISED to +12% to +15%. An AMC print on Aug 10, so Aug 11 was the reaction: $75.35, up 2.34%. Aug 12 handed all of it back, to $73.58. Every headline read the same way: beat, raise, stock up. Almost nobody opened the segment table. Alcon grew net sales 8% - and Equipment, up 25% constant currency, plus eye drops, up 12%, delivered 55% of every dollar of that growth from just 27% of the revenue. Implantables, the premium intraocular lenses the whole multiple is built on, grew 1%. Surgical contribution margin FELL. Vision Care carried the quarter. THE CALL: HOLD (3/5, A CASH MACHINE WITH A STALLED CROWN JEWEL) — base-case value ~$80.52 vs ~$73.58 today. KEY METRICS: - CALL: HOLD, 3/5. Owner-earnings DCF fair value $80.52 vs the $73.58 close of Aug 12 - about 9% ABOVE the tape, between the Street's $76 average and $82 median. Method: 2026E free cash flow $1,764M (H1 $693M; 2025's second half carried 60.7% of the year) less $180M share-based pay = $1,584M owner earnings, grown 8% fading to 3.5% over ten years, terminal 2.5%, at a 7.5% discount rate, less $3,248M net debt, over 488.7M shares. Cross-check 22.7x 2026E core EPS $3.54. Bull $101, bear $61. - THE ANGLE - THE RAZOR SOLD, THE BLADE DID NOT: net sales grew $205M year on year. Equipment/other contributed $57M (+25% cc on a $279M base) and Ocular health $56M (+12% cc on $486M) - 55.1% of all growth from 27.5% of revenue. Implantables contributed $10M, 4.9% of growth, +1% cc on $466M, with the release naming competitive pressures. FY2025 implantables: $1,782M, 0% cc. Eighteen months flat in the highest-margin line Alcon sells. - THE PRINT: net sales $2,782M +8% (+7% cc). Surgical $1,570M and Vision Care $1,212M, both +7% cc. Core operating income $574M +17%, core margin 20.6% vs 19.1%. Core gross margin 64.7% vs 62.2%. Core diluted EPS $0.84 +11%. IFRS operating income $11M, margin 0.4% vs 9.6%; IFRS diluted EPS $0.00. R&D $663M vs $245M. Core adjustments $563M: $402M PowerVision, $128M amortisation, $33M efficiency. Tax was a $46M BENEFIT. - SEGMENT PROFIT AND CASH: Surgical contribution $392M on $1,570M - a 25.0% margin, DOWN from 26.0% on revenue up 7.9%. Vision Care $283M on $1,212M - 23.3%, UP from 18.5%, a 480bp swing. Of the $89M rise in segment profit, $75M (84%) came from Vision Care. H1 free cash flow $693M vs $681M (+1.8%) while core operating income rose 14% - conversion fell 68% to 61%. Net debt $3,248M, ~1.15x EBITDA. What to watch: UP: implantables constant-currency growth breaking above 3% in the November print; UNITY placements converting into premium-lens attach; the $60M tariff refund landing in Q3; free-cash conversion recovering toward last year's 68%. DOWN: another flat implantables quarter as the launch year laps; Equipment decelerating off a 25% comparison; conversion stuck near 61%. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision. Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video Educational only. Not financial advice.